bryan_picture

Glide Pharma confirms Board changes and chairman

pharmafile | October 11, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Glide Pharma, morton 

Pharma development and device firm Glide Pharma has appointed EUSA Pharma’s founder Bryan Morton as a non-executive chairman.

The company also announced that Dr Charles Potter will step down from the Board and his role as Glide’s chief business officer.

Mark Kirby, Glide Pharma’s outgoing chairman, said: “I am pleased to hand over the chairmanship to Bryan. His significant experience of building successful pharmaceutical companies will prove invaluable as Glide begins its next stage of development.”

Advertisement

Morton (pictured) added: “I have been impressed with Glide Pharma’s recent progress, and welcome this opportunity to contribute to the company’s future development. Having completed a significant investment round earlier this year and winning a large funding award from the UK Biomedical Catalyst, the company is well positioned, and I look forward to helping the team exploit the value of Glide’s unique technology.”

Morton has over 30 years’ experience as an entrepreneur and business leader in the life sciences industry. Most recently, he was founder and chief executive of oncology firm EUSA Pharma.

The company was acquired by Jazz Pharmaceuticals in 2012. Prior to this, he founded and led Zeneus Pharma, a European specialty oncology and critical care company, which was subsequently acquired by Cephalon.

Prior to that Morton was president of Convatec, EMEA (Bristol-Myers Squibb), and before this spent 20 years in positions of increasing seniority at Merck & Co. 

Related Content

No items found
The Gateway to Local Adoption Series

Latest content